Barclays lowered the firm’s price target on Elevance Health (ELV) to $358 from $434 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Reports Strong Revenue Growth in Q2 2025
- Elevance Health Earnings Call: Growth Amid Challenges
- Bernstein Calls UnitedHealth Stock (UNH) a Top Pick Ahead of Q2 Earnings
- Cautious Outlook for Elevance Health Amidst Earnings Growth Challenges and Sector Risks
- Elevance Health downgraded to Market Perform from Outperform at Leerink